AdaptHealth (AHCO)
Provides sleep, respiratory, diabetes, and home medical products through insured care channels.
Something off on this page? Send us feedback.
Sells and services home medical equipment, supplies, and care-adjacent products across sleep, respiratory, diabetes, and wellness-at-home categories. The model blends product sales, equipment reimbursement, and capitated contracts while depending on Medicare, Medicaid, commercial payors, licensing, and accreditation.
Provides healthcare-at-home equipment, medical supplies, and related services through Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home. The portfolio covers sleep therapy, oxygen and home ventilation, diabetes devices, durable medical equipment, and wound, urology, ostomy, nutrition, and other home supplies.
Operates across the United States through an acquisition-built national location network. Sleep Health is the largest segment, and large capitated home-equipment contracts are moving from onboarding into operations.
Execution depends on referrals, direct-to-home fulfillment, equipment service, payor reimbursement, supplier enrollment, facility licensing, accreditation, and anti-fraud controls. The roll-up public-company path also leaves acquisition integration, legal-settlement, and goodwill-impairment history.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 17, 2026 | Robert W. Baird | Target | Target: $10 | Target: $9 |
| Aug 6, 2026 | UBS | Reiterate | Rating: —Target: $13 | Target: $10 |
| Aug 6, 2026 | RBC Capital | Reiterate | Rating: —Target: $15 | Target: $8 |
| Aug 5, 2026 | Truist Financial | Target | Target: $12 | Target: $9 |
| Aug 5, 2026 | Robert W. Baird | Target | Target: $15 | Target: $10 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $43.3M · Total debt $2.07B · Total assets $4.34B · Shareholders' equity $1.38B
- Revenue
- $740.3M
- Operating income
- −$137.8M
- Net income
- −$133.9M
No dividends on record.
| Institutions | 105.09% | 143.28M shares | |
|---|---|---|---|
| 253 holders · as of Jun 30, 2026 | |||
| Insiders | 28.61% | 39.01M shares | |
| 22 holders · as of Sep 11, 2026 | |||
| Adds to | 133.70% | ||
136.34M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 133.70%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Oep Capital Advisors, L.P.Institution | 11.96% | 16.31M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 11.78% | 16.06M | as of Jun 30, 2026 |
James E. Flynn1,2Insider10 percent owner, other: *Possible Member of 10% Group | 8.47% | 11.54M | filed Nov 13, 2025 |
Deerfield Management Company, L.P. (Series C)Institution | 8.42% | 11.48M | as of Jun 30, 2026 |
Matthew Ebbel3Insiderdirector | 8.03% | 8.09M · 2.48M | filed Jun 21, 2022 |
- James E. Flynn's transaction reports restate only vehicles that traded; the 2025 ownership statement (11.54M) is used instead.
- James E. Flynn reports a block also reported by Deerfield Management Company, L.P. (Series C); it is counted once, under Deerfield Management Company, L.P. (Series C).
- Matthew Ebbel's transaction reports restate only vehicles that traded; the 2021 ownership statement (8.09M) plus the 374.1K net shares acquired since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 6, 2026 | Dale B. Wolf | director | +40,000 | $6.34 |
| Aug 7, 2026 | Dale B. Wolf | director | +20,000 | $5.86 |
| Aug 6, 2026 | Kenneth A. Samet | director | +23,500 | $6.38 |
| Jul 1, 2026 | III Russell E. Schuster | officer: Chief Commercial Officer | −11,275 | $10.44 |
| Jun 1, 2026 | III Russell E. Schuster | officer: Chief Commercial Officer | −11,275 | $10.06 |
- Linde
Lincare overlaps in national oxygen, ventilation, and PAP services
- Cardinal Health
At-Home Solutions overlaps in direct-to-patient chronic-care supplies
- Viemed Healthcare
Specialized respiratory-care peer in ventilation, PAP, and oxygen
- ResMed
Sleep and breathing device ecosystem pressures the CPAP channel
- Dexcom
CGM platform competes for diabetes-device patient relationships
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| AdaptHealth | $5.76 | −0.09% | $785.0M | — | — | 0.3 | −7.5% |
| Linde | $469.76 | +1.04% | $215.07B | 30.0 | 25.1 | 6.1 | +9.4% |
| Cardinal Health | $222.52 | +0.22% | $52.00B | 30.7 | 17.8 | 0.2 | +5.8% |
| Viemed Healthcare | $8.86 | −1.08% | $341.3M | 24.6 | 18.0 | 1.1 | +23.9% |
| ResMed | $222.45 | +0.22% | $32.20B | 21.3 | 18.3 | 5.7 | +8.6% |
| Dexcom | $88.62 | −1.02% | $33.79B | 35.4 | 31.5 | 6.8 | +13.1% |
| Median | 30.0 | 18.3 | 5.7 | +9.4% |